1
|
Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Regulation of Fibroblast Activation Protein-α Expression: Focus on Intracellular Protein Interactions. J Med Chem 2021; 64:14028-14045. [PMID: 34523930 DOI: 10.1021/acs.jmedchem.1c01010] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The prolyl-specific peptidase fibroblast activation protein-α (FAP-α) is expressed at very low or undetectable levels in nondiseased human tissues but is selectively induced in activated (myo)fibroblasts at sites of tissue remodeling in fibrogenic processes. In normal regenerative processes involving transient fibrosis FAP-α+(myo)fibroblasts disappear from injured tissues, replaced by cells with a normal FAP-α- phenotype. In chronic uncontrolled pathological fibrosis FAP-α+(myo)fibroblasts permanently replace normal tissues. The mechanisms of regulation and elimination of FAP-α expression in(myo)fibroblasts are unknown. According to a yeast two-hybrid screen and protein databanks search, we propose that the intracellular (co)-chaperone BAG6/BAT3 can interact with FAP-α, mediated by the BAG6/BAT3 Pro-rich domain, inducing proteosomal degradation of FAP-α protein under tissue homeostasis. In this Perspective, we discuss our findings in the context of current knowledge on the regulation of FAP-α expression and comment potential therapeutic strategies for uncontrolled fibrosis, including small molecule degraders (PROTACs)-modified FAP-α targeted inhibitors.
Collapse
Affiliation(s)
- Lucienne Juillerat-Jeanneret
- Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), CH1011 Lausanne, Switzerland.,University Institute of Pathology, CHUV and UNIL, CH1011 Lausanne, Switzerland
| | - Petra Tafelmeyer
- Hybrigenics Services, Laboratories and Headquarters-Paris, 1 rue Pierre Fontaine, 91000 Evry, France.,Hybrigenics Corporation, Cambridge Innovation Center, 50 Milk Street, Cambridge, Massachusetts 02142, United States
| | - Dela Golshayan
- Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), CH1011 Lausanne, Switzerland
| |
Collapse
|
2
|
Juillerat-Jeanneret L. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? J Med Chem 2013; 57:2197-212. [PMID: 24099035 DOI: 10.1021/jm400658e] [Citation(s) in RCA: 138] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X-Pro/Ala dipeptides from the N-terminus of peptides. DPP IV is responsible of the degradation of the incretin peptide hormones regulating blood glucose levels. Several families of DPP IV inhibitors have been synthesized and evaluated. Their positive effects on the degradation of the incretins and the control of blood glucose levels have been demonstrated in biological models and in clinical trials. Presently, several DPP IV inhibitors, the "gliptins", are approved for type 2 diabetes or are under clinical evaluation. However, the gliptins may also be of therapeutic interest for other diseases beyond the inhibition of incretin degradation. In this Perspective, the biological functions and potential substrates of DPP IV enzymes are reviewed and the characteristics of the DPP IV inhibitors are discussed in view of type 2 diabetes and further therapeutic interest.
Collapse
|
3
|
Juillerat-Jeanneret L, Robert MC, Juillerat MA. Peptides from Lactobacillus hydrolysates of bovine milk caseins inhibit prolyl-peptidases of human colon cells. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2011; 59:370-377. [PMID: 21126072 DOI: 10.1021/jf102803a] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Prolyl-rich peptides derived from hydrolysates of bovine caseins have been previously shown to inhibit angiotensin converting enzyme (ACE) activity, suggesting that they may also be able to inhibit the enzymatic activities of prolyl-specific peptidases. This study shows that peptides derived from α(S1)-casein and β-casein inhibited the enzymatic activities of purified recombinant matrix metalloprotease (MMP)-2, MMP-7, and MMP-9. The inhibitory efficacy was sequence-dependent. These peptides also selectively inhibited the enzymatic activities of prolyl-amino-peptidases, prolyl-amino-dipeptidases, and prolyl-endopeptidases in extracts of HT-29 and SW480 human colon carcinoma cells, but not in intact cells. They were not cytotoxic or growth inhibitory for these cells. Thus, the prolyl-rich selected peptides were good and selective inhibitors of MMPs and post-proline-cleaving proteases, demonstrating their potential to control inadequate proteolytic activity in the human digestive tract, without inducing cytotoxic effects.
Collapse
Affiliation(s)
- Lucienne Juillerat-Jeanneret
- University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV), and University of Lausanne (UNIL), Lausanne, Switzerland.
| | | | | |
Collapse
|
5
|
Millon SR, Ostrander JH, Yazdanfar S, Brown JQ, Bender JE, Rajeha A, Ramanujam N. Preferential accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in breast cancer: a comprehensive study on six breast cell lines with varying phenotypes. JOURNAL OF BIOMEDICAL OPTICS 2010; 15:018002. [PMID: 20210488 PMCID: PMC2839804 DOI: 10.1117/1.3302811] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2009] [Revised: 10/26/2009] [Accepted: 11/30/2009] [Indexed: 05/28/2023]
Abstract
We describe the potential of 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) fluorescence as a source of contrast for margin detection in commonly diagnosed breast cancer subtypes. Fluorescence intensity of PpIX in untreated and ALA-treated normal mammary epithelial and breast cancer cell lines of varying estrogen receptor expression were quantitatively imaged with confocal microscopy. Percentage change in fluorescence intensity integrated over 610-700 nm (attributed to PpIX) of posttreated compared to pretreated cells showed statistically significant differences between four breast cancer and two normal mammary epithelial cell lines. However, a direct comparison of post-treatment PpIX fluorescence intensities showed no differences between breast cancer and normal mammary epithelial cell lines due to confounding effects by endogenous fluorescence from flavin adenine dinucleotide (FAD). Clinically, it is impractical to obtain pre- and post-treatment images. Thus, spectral imaging was demonstrated as a means to remove the effects of endogenous FAD fluorescence allowing for discrimination between post-treatment PpIX fluorescence of four breast cancer and two normal mammary epithelial cell lines. Fluorescence spectral imaging of ALA-treated breast cancer cells showed preferential PpIX accumulation regardless of malignant phenotype and suggests a useful contrast mechanism for discrimination of residual cancer at the surface of breast tumor margins.
Collapse
Affiliation(s)
- Stacy R Millon
- Duke University, Department of Biomedical Engineering, Durham, North Carolina 27708-0281, USA.
| | | | | | | | | | | | | |
Collapse
|
6
|
Vallinayagam R, Schmitt F, Barge J, Wagnieres G, Wenger V, Neier R, Juillerat-Jeanneret L. Glycoside Esters of 5-Aminolevulinic Acid for Photodynamic Therapy of Cancer. Bioconjug Chem 2008; 19:821-39. [DOI: 10.1021/bc700324r] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Ramakrishnan Vallinayagam
- Institute of Chemistry, Neuchâtel University, avenue de Bellevaux, P.O. Box 2, CH-2007 Neuchâtel, Switzerland, University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Bugnon 25, CH-1011 Lausanne, Switzerland, and Swiss Federal Institute of Technology (EPFL), Laboratory of Photomedicine, EPFL, CH-1015 Lausanne, Switzerland
| | - Frédéric Schmitt
- Institute of Chemistry, Neuchâtel University, avenue de Bellevaux, P.O. Box 2, CH-2007 Neuchâtel, Switzerland, University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Bugnon 25, CH-1011 Lausanne, Switzerland, and Swiss Federal Institute of Technology (EPFL), Laboratory of Photomedicine, EPFL, CH-1015 Lausanne, Switzerland
| | - Jérome Barge
- Institute of Chemistry, Neuchâtel University, avenue de Bellevaux, P.O. Box 2, CH-2007 Neuchâtel, Switzerland, University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Bugnon 25, CH-1011 Lausanne, Switzerland, and Swiss Federal Institute of Technology (EPFL), Laboratory of Photomedicine, EPFL, CH-1015 Lausanne, Switzerland
| | - Georges Wagnieres
- Institute of Chemistry, Neuchâtel University, avenue de Bellevaux, P.O. Box 2, CH-2007 Neuchâtel, Switzerland, University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Bugnon 25, CH-1011 Lausanne, Switzerland, and Swiss Federal Institute of Technology (EPFL), Laboratory of Photomedicine, EPFL, CH-1015 Lausanne, Switzerland
| | - Virginie Wenger
- Institute of Chemistry, Neuchâtel University, avenue de Bellevaux, P.O. Box 2, CH-2007 Neuchâtel, Switzerland, University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Bugnon 25, CH-1011 Lausanne, Switzerland, and Swiss Federal Institute of Technology (EPFL), Laboratory of Photomedicine, EPFL, CH-1015 Lausanne, Switzerland
| | - Reinhard Neier
- Institute of Chemistry, Neuchâtel University, avenue de Bellevaux, P.O. Box 2, CH-2007 Neuchâtel, Switzerland, University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Bugnon 25, CH-1011 Lausanne, Switzerland, and Swiss Federal Institute of Technology (EPFL), Laboratory of Photomedicine, EPFL, CH-1015 Lausanne, Switzerland
| | - Lucienne Juillerat-Jeanneret
- Institute of Chemistry, Neuchâtel University, avenue de Bellevaux, P.O. Box 2, CH-2007 Neuchâtel, Switzerland, University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Bugnon 25, CH-1011 Lausanne, Switzerland, and Swiss Federal Institute of Technology (EPFL), Laboratory of Photomedicine, EPFL, CH-1015 Lausanne, Switzerland
| |
Collapse
|